Crucell, da schlummert ein Riese in Amsterdam - 500 Beiträge pro Seite
eröffnet am 27.11.03 13:12:31 von
neuester Beitrag 26.01.04 13:29:18 von
neuester Beitrag 26.01.04 13:29:18 von
Beiträge: 9
ID: 799.710
ID: 799.710
Aufrufe heute: 0
Gesamt: 716
Gesamt: 716
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 5553 | |
| heute 11:09 | 3425 | |
| vor 58 Minuten | 2116 | |
| vor 48 Minuten | 2012 | |
| heute 09:10 | 1722 | |
| vor 42 Minuten | 1623 | |
| vor 1 Stunde | 1418 | |
| vor 1 Stunde | 1312 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.955,76 | -0,73 | 220 | |||
| 2. | 3. | 150,94 | -0,41 | 104 | |||
| 3. | 2. | 9,5200 | -1,30 | 93 | |||
| 4. | 4. | 0,1875 | -3,35 | 77 | |||
| 5. | 34. | 0,6250 | -55,36 | 47 | |||
| 6. | 13. | 395,40 | -14,33 | 43 | |||
| 7. | 6. | 0,0211 | -32,59 | 41 | |||
| 8. | 5. | 6,8340 | +1,33 | 40 |
Feedback
was wisst Ihr über dieses Unternehmen ????
kaum Handel in Deutschland .............
the train is leaving the station .........
m e r x
kaum Handel in Deutschland .............
the train is leaving the station .........
m e r x
steigende Umsätze mit großen Blöcken in Amsterdam und
in den USA, mag es wohl an dieser Meldung gelegen haben ???
Friday, December 12, 2003 - Page updated at 12:00 A.M.
Treatment for deadly Ebola virus advances
By Emma Ross
The Associated Press
E-mail this article
Print this article
Search archive
LONDON — The first treatment to show promise against the deadly Ebola virus has cured one-third of the monkeys on which it was tested — raising hopes that a lifesaving therapy for people may be on the horizon.
Experts said the results represent the biggest advance yet in the quest for a drug against Ebola Hemorrhagic Fever, one of the most feared diseases. World Health Organization doctors said they plan to try the drug on humans during the next outbreak.
"You take the patients from their families, they die in the ward, you bury them. Everybody is dying, and you cannot do anything," said WHO Ebola expert Pierre Formenty, speaking from the front line of the latest outbreak in Congo. "If you can save one or two, it will be nice to come back and try to save lives and not just control outbreaks by burying people."
In the study, outlined this week in The Lancet medical journal, scientists at the U.S. Army Medical Research Institute of Infectious Diseases used a protein that blocks blood coagulation, considered to be a major problem in the disease.
Although it is called Ebola Hemorrhagic Fever, bleeding occurs in only about 40 percent of cases and often is not the cause of death. The affliction is so named because when there is hemorrhage, it is dramatic. The disease most often involves a shock syndrome in which multiple organs shut down at once.
The death rate varies from about 50 percent for milder strains of the virus to about 90 percent for the Zaire strain, which is ravaging the community in Mbomo, deep in the bush of Congo. Since the outbreak began in October, 31 people have been infected and 29 have died.
Scientists believe the virus cranks up the body`s production of a substance called tissue factor, which is involved in making blood clots. The body`s ability to regulate the thickness of the blood goes awry, clots start to congest the blood vessels and blood backs up, said the study`s leader, Army virologist Thomas Geisbert.
Many strategies have cured mice and other rodents of Ebola but didn`t work when tried in monkeys.
In this study, researchers injected 12 monkeys with a high dose of the Zaire strain of the Ebola virus, which is 100 percent fatal in monkeys.
Then, starting either 10 minutes after the lethal injection or 24 hours later, the scientists gave nine of the monkeys daily shots of the anticoagulation protein for 14 days. The other three monkeys received fake injections.
Tests showed clotting activity was dampened in the monkeys that received the treatment.
Three of the nine monkeys treated, or 33 percent, lived. All the monkeys who received the fake treatment died.
"We saved the lives of three out of nine monkeys," Geisbert said. "They are still eating biscuits in my lab. The virus is gone. They are healthy. They are cured."
Almost as impressive was the finding that those monkeys that were treated but died anyway survived for an average of 12 days — about four days longer than monkeys who had not received the treatment.
Experts said that delay in death could be crucial.
"What we`re doing with Ebola is we`re buying time. The difference between Ebola and AIDS is that with Ebola, you do have the possibility of an immune response and to get well — if you can hang around long enough," said C.J. Peters, director for biodefense at the Center for Biodefense and Emerging Infectious Diseases at University of Texas Medical Branch in Galveston, Texas.
Peters said the monkey results are encouraging for humans because they provide a stringent test. If anything, he said, death rates from Ebola are higher in monkeys than in humans.
In another advance in the battle against Ebola, WHO scientists reported success with a new diagnostic test they used for the first time in the Mbomo outbreak.
Formenty said a simple dipstick that turns blue in the presence of Ebola seems as accurate as genetic tests that are not practical for rural areas of Africa, where most Ebola outbreaks occur.
Emergency workers try to determine who has Ebola by observing patients` symptoms and asking about their contacts.
Copyright © 2003 The Seattle Times Company
More health & science headlines
Gruß
m e r x
in den USA, mag es wohl an dieser Meldung gelegen haben ???
Friday, December 12, 2003 - Page updated at 12:00 A.M.
Treatment for deadly Ebola virus advances
By Emma Ross
The Associated Press
E-mail this article
Print this article
Search archive
LONDON — The first treatment to show promise against the deadly Ebola virus has cured one-third of the monkeys on which it was tested — raising hopes that a lifesaving therapy for people may be on the horizon.
Experts said the results represent the biggest advance yet in the quest for a drug against Ebola Hemorrhagic Fever, one of the most feared diseases. World Health Organization doctors said they plan to try the drug on humans during the next outbreak.
"You take the patients from their families, they die in the ward, you bury them. Everybody is dying, and you cannot do anything," said WHO Ebola expert Pierre Formenty, speaking from the front line of the latest outbreak in Congo. "If you can save one or two, it will be nice to come back and try to save lives and not just control outbreaks by burying people."
In the study, outlined this week in The Lancet medical journal, scientists at the U.S. Army Medical Research Institute of Infectious Diseases used a protein that blocks blood coagulation, considered to be a major problem in the disease.
Although it is called Ebola Hemorrhagic Fever, bleeding occurs in only about 40 percent of cases and often is not the cause of death. The affliction is so named because when there is hemorrhage, it is dramatic. The disease most often involves a shock syndrome in which multiple organs shut down at once.
The death rate varies from about 50 percent for milder strains of the virus to about 90 percent for the Zaire strain, which is ravaging the community in Mbomo, deep in the bush of Congo. Since the outbreak began in October, 31 people have been infected and 29 have died.
Scientists believe the virus cranks up the body`s production of a substance called tissue factor, which is involved in making blood clots. The body`s ability to regulate the thickness of the blood goes awry, clots start to congest the blood vessels and blood backs up, said the study`s leader, Army virologist Thomas Geisbert.
Many strategies have cured mice and other rodents of Ebola but didn`t work when tried in monkeys.
In this study, researchers injected 12 monkeys with a high dose of the Zaire strain of the Ebola virus, which is 100 percent fatal in monkeys.
Then, starting either 10 minutes after the lethal injection or 24 hours later, the scientists gave nine of the monkeys daily shots of the anticoagulation protein for 14 days. The other three monkeys received fake injections.
Tests showed clotting activity was dampened in the monkeys that received the treatment.
Three of the nine monkeys treated, or 33 percent, lived. All the monkeys who received the fake treatment died.
"We saved the lives of three out of nine monkeys," Geisbert said. "They are still eating biscuits in my lab. The virus is gone. They are healthy. They are cured."
Almost as impressive was the finding that those monkeys that were treated but died anyway survived for an average of 12 days — about four days longer than monkeys who had not received the treatment.
Experts said that delay in death could be crucial.
"What we`re doing with Ebola is we`re buying time. The difference between Ebola and AIDS is that with Ebola, you do have the possibility of an immune response and to get well — if you can hang around long enough," said C.J. Peters, director for biodefense at the Center for Biodefense and Emerging Infectious Diseases at University of Texas Medical Branch in Galveston, Texas.
Peters said the monkey results are encouraging for humans because they provide a stringent test. If anything, he said, death rates from Ebola are higher in monkeys than in humans.
In another advance in the battle against Ebola, WHO scientists reported success with a new diagnostic test they used for the first time in the Mbomo outbreak.
Formenty said a simple dipstick that turns blue in the presence of Ebola seems as accurate as genetic tests that are not practical for rural areas of Africa, where most Ebola outbreaks occur.
Emergency workers try to determine who has Ebola by observing patients` symptoms and asking about their contacts.
Copyright © 2003 The Seattle Times Company
More health & science headlines
Gruß
m e r x
Ein kleiner Überblick über die Aktivitäten von Crucell:
Crucell Presents Update on In-house Product Development Programs at Analyst Meeting
Crucell`s influenza epidemic vaccine program has been expanded to include a pandemic vaccine. The company expects to file INDs for both the pandemic and epidemic vaccines in 2005.
Crucell`s recombinant Ebola vaccine is currently in pre-clinical development, with results expected during the first half of 2004. If the outcome is favorable, Crucell expects to file an IND in 2004.
Crucell is developing a human West Nile vaccine in-house and a veterinary vaccine in collaboration with Kimron Institute in Israel. Both vaccines are based on an inactivated whole virus technology, which has a proven record of efficacy and safety, and use Crucell`s unique PER.C6(TM) technology. For the human vaccine, the company expects to complete pre-clinical studies in geese and monkeys by the end of 2004. Pending the outcome of these studies, the human vaccine should enter Phase I clinical development in 2005. Crucell and Kimron Veterinary Institute anticipate approval of the veterinary vaccine early 2004.
Crucell`s malaria vaccine concept, based on the collaboration with GlaxoSmithKline Biologicals and Walter Reed Army Institute of Research, showed promising results in the mouse malaria model. Further results in monkeys demonstrating the potency of the AdVac(TM)-based human malaria vaccine, are expected in the first half of 2004.
Crucell expressed confidence in the competitive position of their vaccine programs based on the specific development approaches and novel technologies that they have selected. The company announced completion of key development facilities and the opening of a liaison office in the U.S. to support the execution of its development plans.
Crucell`s current cash reserves are over 90 million. Management expects that its currently available cash, combined with on-going revenues received from technology licensing contracts and government grants, will be adequate to fund the company`s development programs until it reaches break-even.
The Analyst Meeting can be viewed via live video webcast at 1.00pm CET on Crucell`s website at www.crucell.com. The video webcast will be archived and available for replay following the event.
About Crucell Crucell N.V. is a biotechnology company dedicated to developing products that prevent and treat infectious diseases. Crucell leverages its unique PER.C6(TM) production technology to develop a broad range of vaccines and antibodies. The company`s development activities include collaborations with the U.S. National Institutes of Health, the U.S. Army, GlaxoSmithKline (GSK), Harvard Medical School and New York University. In addition, Crucell licenses its PER.C6(TM) production technology to the biopharmaceutical industry independently and through partnerships with contract manufacturing organizations such as DSM Biologicals. Licensees include Merck & Co. Inc., for its HIV vaccine, GSK, Centocor/J&J and Aventis. Crucell is headquartered in Leiden, The Netherlands, and currently employs 180 people. Crucell is listed on Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information visit www.crucell.com.
This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 18, 2003, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).
For the PDF file of the press release, please click on the following link:
copyright © Hugin ASA. All rights reserved.
Crucell Presents Update on In-house Product Development Programs at Analyst Meeting
Crucell`s influenza epidemic vaccine program has been expanded to include a pandemic vaccine. The company expects to file INDs for both the pandemic and epidemic vaccines in 2005.
Crucell`s recombinant Ebola vaccine is currently in pre-clinical development, with results expected during the first half of 2004. If the outcome is favorable, Crucell expects to file an IND in 2004.
Crucell is developing a human West Nile vaccine in-house and a veterinary vaccine in collaboration with Kimron Institute in Israel. Both vaccines are based on an inactivated whole virus technology, which has a proven record of efficacy and safety, and use Crucell`s unique PER.C6(TM) technology. For the human vaccine, the company expects to complete pre-clinical studies in geese and monkeys by the end of 2004. Pending the outcome of these studies, the human vaccine should enter Phase I clinical development in 2005. Crucell and Kimron Veterinary Institute anticipate approval of the veterinary vaccine early 2004.
Crucell`s malaria vaccine concept, based on the collaboration with GlaxoSmithKline Biologicals and Walter Reed Army Institute of Research, showed promising results in the mouse malaria model. Further results in monkeys demonstrating the potency of the AdVac(TM)-based human malaria vaccine, are expected in the first half of 2004.
Crucell expressed confidence in the competitive position of their vaccine programs based on the specific development approaches and novel technologies that they have selected. The company announced completion of key development facilities and the opening of a liaison office in the U.S. to support the execution of its development plans.
Crucell`s current cash reserves are over 90 million. Management expects that its currently available cash, combined with on-going revenues received from technology licensing contracts and government grants, will be adequate to fund the company`s development programs until it reaches break-even.
The Analyst Meeting can be viewed via live video webcast at 1.00pm CET on Crucell`s website at www.crucell.com. The video webcast will be archived and available for replay following the event.
About Crucell Crucell N.V. is a biotechnology company dedicated to developing products that prevent and treat infectious diseases. Crucell leverages its unique PER.C6(TM) production technology to develop a broad range of vaccines and antibodies. The company`s development activities include collaborations with the U.S. National Institutes of Health, the U.S. Army, GlaxoSmithKline (GSK), Harvard Medical School and New York University. In addition, Crucell licenses its PER.C6(TM) production technology to the biopharmaceutical industry independently and through partnerships with contract manufacturing organizations such as DSM Biologicals. Licensees include Merck & Co. Inc., for its HIV vaccine, GSK, Centocor/J&J and Aventis. Crucell is headquartered in Leiden, The Netherlands, and currently employs 180 people. Crucell is listed on Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information visit www.crucell.com.
This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 18, 2003, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).
For the PDF file of the press release, please click on the following link:
copyright © Hugin ASA. All rights reserved.
und sie steigt und steigt und steigt...................
wer weis wohin ??????????????????????
wer weis wohin ??????????????????????
Press Release Source: Galapagos Genomics
Bayer Healthcare and Galapagos in Target Discovery Collaboration
Tuesday December 16, 2:11 am ET
MECHELEN, Belgium, Dec. 16, 2003 (PRIMEZONE) -- Galapagos Genomics today announced a target discovery collaboration with Bayer HealthCare AG. Within the partnership, the Companies will collaborate to discover and validate novel drug targets for Bayer`s disease areas. Galapagos will use its disease biology expertise in combination with its SilenceSelect(tm) and FLeXSelect(tm) target discovery collections to identify and validate drugable targets. Under the terms of the agreement, Bayer HealthCare has the exclusive right to select validated targets for drug development in return for upfront payments, research funding and milestones. Further financial terms were not disclosed.
ADVERTISEMENT
``We are very pleased to be selected by Bayer HealthCare,`` said Onno van de Stolpe, CEO of Galapagos. ``This partnership again underlines the competitive edge of our Company in combining our SilenceSelect and FLeXSelect libraries with high throughput disease biology.``
SilenceSelect is a collection of adenoviruses with siRNA based knock-down sequences targeting over 4,000 human drugable genes, where drugable represents those gene classes of most value for pharmaceutical development. FLeXSelect is the mirror collection of adenoviruses with full length genes from the drugable gene classes. These two collections in combination with cellular assays enable the rapid functional discovery of proteins that are directly involved in a specific disease process. In this partnership, Galapagos will design cellular assays in disease areas of interest to Bayer, and subsequently screen the SilenceSelect and FLeXSelect gene collections to identify and validate targets that will proceed into drug discovery by Bayer.
About Bayer HealthCare AG
Bayer HealthCare AG, a subgroup of Bayer AG, with sales of approximately 9,4 billion Euro in 2002, is one of the world`s leading, innovative companies in the health care and medical products industry. The company combines the global activities of the divisions Animal Health, Biological Products, Consumer Care, Diagnostics and Pharmaceuticals. More than 34,000 people are employed by Bayer HealthCare worldwide. Its aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Its products enhance well-being and quality of life by diagnosing, preventing and treating disease.
About Galapagos Genomics NV
Galapagos Genomics is a discovery company focused on the rapid identification and validation of disease modifying drug targets by functional screening in human disease models. The research activities encompass the internal programs in osteoporosis, rheumatoid arthritis, osteoarthritis and Alzheimer`s disease, as well as numerous partnerships with leading pharmaceutical, nutraceutical and biotech companies. Proprietary targets resulting from our internal programs are used for the development of drugs in our core disease areas, combined with selected out-licensing and partnering of projects during development. The Company currently employs 90 people, including 22 PhD`s, and occupies a 2000 sq.m. research and production facility in Mechelen, with additional research laboratories in Leiden, The Netherlands. Galapagos` other partners include Boehringer Ingelheim, Euroscreen, Exelixis, Incyte, Johnson&Johnson, Organon, Pfizer, Procter&Gamble, UCB Pharma, Vertex and Wyeth. Galapagos was founded in 1999 by Crucell (NasdaqNM:CRXL - News) (Euronext:CRXL) and Tibotec to exploit Crucell`s unique PER.C6(tm) technology for target discovery. The shareholders are Abingworth Management, Apax Partners, Burrill&Company, NIB Capital Private Equity, Crucell Holland BV and Tibotec-Virco NV. More information on Galapagos can be found at the website http://www.galapagosgenomics.com. SilenceSelect and FLeXSelect are pending trademarks owned by Galapagos Genomics NV.
Contact:
Galapagos Genomics
Onno van de Stolpe, CEO
+31 6290 980 28
onno@galapagos.be
--------------------------------------------------------------------------------
Source: Galapagos Genomics
Email this story - Set a News Alert
Bayer Healthcare and Galapagos in Target Discovery Collaboration
Tuesday December 16, 2:11 am ET
MECHELEN, Belgium, Dec. 16, 2003 (PRIMEZONE) -- Galapagos Genomics today announced a target discovery collaboration with Bayer HealthCare AG. Within the partnership, the Companies will collaborate to discover and validate novel drug targets for Bayer`s disease areas. Galapagos will use its disease biology expertise in combination with its SilenceSelect(tm) and FLeXSelect(tm) target discovery collections to identify and validate drugable targets. Under the terms of the agreement, Bayer HealthCare has the exclusive right to select validated targets for drug development in return for upfront payments, research funding and milestones. Further financial terms were not disclosed.
ADVERTISEMENT
``We are very pleased to be selected by Bayer HealthCare,`` said Onno van de Stolpe, CEO of Galapagos. ``This partnership again underlines the competitive edge of our Company in combining our SilenceSelect and FLeXSelect libraries with high throughput disease biology.``
SilenceSelect is a collection of adenoviruses with siRNA based knock-down sequences targeting over 4,000 human drugable genes, where drugable represents those gene classes of most value for pharmaceutical development. FLeXSelect is the mirror collection of adenoviruses with full length genes from the drugable gene classes. These two collections in combination with cellular assays enable the rapid functional discovery of proteins that are directly involved in a specific disease process. In this partnership, Galapagos will design cellular assays in disease areas of interest to Bayer, and subsequently screen the SilenceSelect and FLeXSelect gene collections to identify and validate targets that will proceed into drug discovery by Bayer.
About Bayer HealthCare AG
Bayer HealthCare AG, a subgroup of Bayer AG, with sales of approximately 9,4 billion Euro in 2002, is one of the world`s leading, innovative companies in the health care and medical products industry. The company combines the global activities of the divisions Animal Health, Biological Products, Consumer Care, Diagnostics and Pharmaceuticals. More than 34,000 people are employed by Bayer HealthCare worldwide. Its aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Its products enhance well-being and quality of life by diagnosing, preventing and treating disease.
About Galapagos Genomics NV
Galapagos Genomics is a discovery company focused on the rapid identification and validation of disease modifying drug targets by functional screening in human disease models. The research activities encompass the internal programs in osteoporosis, rheumatoid arthritis, osteoarthritis and Alzheimer`s disease, as well as numerous partnerships with leading pharmaceutical, nutraceutical and biotech companies. Proprietary targets resulting from our internal programs are used for the development of drugs in our core disease areas, combined with selected out-licensing and partnering of projects during development. The Company currently employs 90 people, including 22 PhD`s, and occupies a 2000 sq.m. research and production facility in Mechelen, with additional research laboratories in Leiden, The Netherlands. Galapagos` other partners include Boehringer Ingelheim, Euroscreen, Exelixis, Incyte, Johnson&Johnson, Organon, Pfizer, Procter&Gamble, UCB Pharma, Vertex and Wyeth. Galapagos was founded in 1999 by Crucell (NasdaqNM:CRXL - News) (Euronext:CRXL) and Tibotec to exploit Crucell`s unique PER.C6(tm) technology for target discovery. The shareholders are Abingworth Management, Apax Partners, Burrill&Company, NIB Capital Private Equity, Crucell Holland BV and Tibotec-Virco NV. More information on Galapagos can be found at the website http://www.galapagosgenomics.com. SilenceSelect and FLeXSelect are pending trademarks owned by Galapagos Genomics NV.
Contact:
Galapagos Genomics
Onno van de Stolpe, CEO
+31 6290 980 28
onno@galapagos.be
--------------------------------------------------------------------------------
Source: Galapagos Genomics
Email this story - Set a News Alert
Trading Spotlight
Reuters
UPDATE - Run on flu vaccine highlights vaccine woes
Tuesday December 16, 4:00 pm ET
By Maggie Fox, Health and Science Correspondent
(Previous CHICAGO, writes through with outside commentary)
WASHINGTON, Dec 16 (Reuters) - The current run on influenza vaccine in United States highlights the neglected status of vaccines in general, health experts said on Tuesday -- but efforts are under way to improve vaccine technology and supply.
They said sporadic shortages of vaccines routinely given to children for mumps, measles, diphtheria and other diseases are likely to continue unless some changes are made.
And regular shortages of influenza vaccine can also be expected unless some changes are made.
In a report published in Wednesday`s issue of the Journal of the American Medical Association (News - Websites) , the National Vaccine Advisory Committee recommended increased government funding for vaccine stockpiles.
The group also advised stronger liability protections for manufacturers; a requirement that manufacturers give advance notice if they are leaving the marketplace; and a national campaign to emphasize the safety and benefits of vaccines.
The U.S. government has bought 625,000 doses of flu vaccine from two makers -- Emeryville, California-based Chiron Corp. (NasdaqNM:CHIR - News) and a U.S. subsidiary of French-based Aventis (Paris:AVEP.PA - News) -- to try and cover the demand.
It has also negotiated a discount price for states to buy up to 3 million doses of Wyeth (NYSE:WYE - News) and MedImmune`s (NasdaqNM:MEDI - News) FluMist vaccine, which can be given nasally.
Health experts say the demand -- brought on by media coverage of an unusually early flu season in the United States -- illustrates the dilemma over vaccines.
PREVENTION NOT VALUED
"We don`t value prevention in this country," said Dr. Paul Offit of Children`s Hospital of Philadelphia and a leading vaccine expert.
The current shortage only affects some areas and some doctors` offices, but it is only the latest in a series of flu vaccine shortages. The most recent was in 2000.
And in 2001-2002 there were serious shortages of childhood vaccinations, including immunizations for measles, pneumococcal disease and tetanus.
Despite the huge amount of publicity surrounding the shortages, people still do not get their influenza vaccines, said Dr. Julie Gerberding, head of the U.S. Centers for Disease Control and Prevention.
"We believe that about 185 million people in this country are at risk from influenza and we never get anywhere near that number vaccinated," Gerberding to a news conference last week.
One reason the influenza vaccine is in short supply this year is that last year Aventis and Chiron made 95 million doses, but had to throw 12 million away because people didn`t get immunized. This year, they made 83 million doses.
There was no way for them to hurry up and make more when this year`s flu season started early.
"To scale it up we would have to change the whole approach," Gerberding said. Now flu vaccines are grown in eggs and it is a time-consuming process.
"We know we need more research to be able to use tissue culture based vaccine," Gerberding said. Another way to quickly change the vaccine would rely on genetic engineering to precisely tailor the vaccine to keep up with the quickly mutating virus.
Offit said another problem is that there are so few vaccine makers.
"The measles, mumps and rubella vaccine -- there one vaccine maker," he said. "Varicella (chickenpox) -- one maker. The result is we don`t have a very nimble system. When shortages occur we don`t have stockpiles we can go to."
(Additional reporting by Mike Conlon in Chicago)
Email this story - Set a News Alert
UPDATE - Run on flu vaccine highlights vaccine woes
Tuesday December 16, 4:00 pm ET
By Maggie Fox, Health and Science Correspondent
(Previous CHICAGO, writes through with outside commentary)
WASHINGTON, Dec 16 (Reuters) - The current run on influenza vaccine in United States highlights the neglected status of vaccines in general, health experts said on Tuesday -- but efforts are under way to improve vaccine technology and supply.
They said sporadic shortages of vaccines routinely given to children for mumps, measles, diphtheria and other diseases are likely to continue unless some changes are made.
And regular shortages of influenza vaccine can also be expected unless some changes are made.
In a report published in Wednesday`s issue of the Journal of the American Medical Association (News - Websites) , the National Vaccine Advisory Committee recommended increased government funding for vaccine stockpiles.
The group also advised stronger liability protections for manufacturers; a requirement that manufacturers give advance notice if they are leaving the marketplace; and a national campaign to emphasize the safety and benefits of vaccines.
The U.S. government has bought 625,000 doses of flu vaccine from two makers -- Emeryville, California-based Chiron Corp. (NasdaqNM:CHIR - News) and a U.S. subsidiary of French-based Aventis (Paris:AVEP.PA - News) -- to try and cover the demand.
It has also negotiated a discount price for states to buy up to 3 million doses of Wyeth (NYSE:WYE - News) and MedImmune`s (NasdaqNM:MEDI - News) FluMist vaccine, which can be given nasally.
Health experts say the demand -- brought on by media coverage of an unusually early flu season in the United States -- illustrates the dilemma over vaccines.
PREVENTION NOT VALUED
"We don`t value prevention in this country," said Dr. Paul Offit of Children`s Hospital of Philadelphia and a leading vaccine expert.
The current shortage only affects some areas and some doctors` offices, but it is only the latest in a series of flu vaccine shortages. The most recent was in 2000.
And in 2001-2002 there were serious shortages of childhood vaccinations, including immunizations for measles, pneumococcal disease and tetanus.
Despite the huge amount of publicity surrounding the shortages, people still do not get their influenza vaccines, said Dr. Julie Gerberding, head of the U.S. Centers for Disease Control and Prevention.
"We believe that about 185 million people in this country are at risk from influenza and we never get anywhere near that number vaccinated," Gerberding to a news conference last week.
One reason the influenza vaccine is in short supply this year is that last year Aventis and Chiron made 95 million doses, but had to throw 12 million away because people didn`t get immunized. This year, they made 83 million doses.
There was no way for them to hurry up and make more when this year`s flu season started early.
"To scale it up we would have to change the whole approach," Gerberding said. Now flu vaccines are grown in eggs and it is a time-consuming process.
"We know we need more research to be able to use tissue culture based vaccine," Gerberding said. Another way to quickly change the vaccine would rely on genetic engineering to precisely tailor the vaccine to keep up with the quickly mutating virus.
Offit said another problem is that there are so few vaccine makers.
"The measles, mumps and rubella vaccine -- there one vaccine maker," he said. "Varicella (chickenpox) -- one maker. The result is we don`t have a very nimble system. When shortages occur we don`t have stockpiles we can go to."
(Additional reporting by Mike Conlon in Chicago)
Email this story - Set a News Alert
und schon wieder 8% am Freitagabend in den USA.
Na Jungs , schaut mal am Montagmorgen nach Amsterdam.
Up, up and away...............
merx
Na Jungs , schaut mal am Montagmorgen nach Amsterdam.
Up, up and away...............
merx
Reuters
UPDATE - Crucell shares jump on Aventis flu vaccine news
Wednesday January 7, 10:50 am ET
(Adds details, share reaction, trader comment)
NEW YORK/AMSTERDAM, Jan 7 (Reuters) - European drugmakers Aventis (Paris:AVEP.PA - News) and Crucell (Amsterdam:CRCL.AS - News) said on Wednesday they had agreed to further develop and sell a new type of flu vaccine that is easier to make than current vaccines.
ADVERTISEMENT
The news boosted shares in small-cap firm Crucell and at 1523 GMT the stock traded 21.1 percent higher at 6.36 euros.
"It is a lot of money for a company such as Crucell and it shows they have products for which there is demand," said senior sales trader Jan-Paul Raterink at Dutch broker Delta Lloyd.
Under the deal, Aventis` vaccine division will license Crucell`s cell line technology to make the vaccines and will in return give Crucell (NasdaqNM:CRXL - News) payments and research funding totaling $38 million.
Aventis, a Franco-German drugmaker which is one of world`s few makers of flu vaccines, would also give Netherlands-based Crucell royalties on vaccine sales in the high-single-digit to double-digit percentage range.
But Raterink added that various questions were left unanswered, such as the timeframe over which the Aventis payments would be received by Crucell.
"With a current market capitalisation of 228 or 229 million euros, Crucell`s share price jump of over 20 percent implies that future gains have already been factored in now," he added.
Aventis shares were more than two percent lower at 50.95 euros in afternoon trade.
Email this story - Set a News Alert
was sag ich schon so lange............
it`s a blockbuster............
up, up and away...........
Grüße
m e r x,
UPDATE - Crucell shares jump on Aventis flu vaccine news
Wednesday January 7, 10:50 am ET
(Adds details, share reaction, trader comment)
NEW YORK/AMSTERDAM, Jan 7 (Reuters) - European drugmakers Aventis (Paris:AVEP.PA - News) and Crucell (Amsterdam:CRCL.AS - News) said on Wednesday they had agreed to further develop and sell a new type of flu vaccine that is easier to make than current vaccines.
ADVERTISEMENT
The news boosted shares in small-cap firm Crucell and at 1523 GMT the stock traded 21.1 percent higher at 6.36 euros.
"It is a lot of money for a company such as Crucell and it shows they have products for which there is demand," said senior sales trader Jan-Paul Raterink at Dutch broker Delta Lloyd.
Under the deal, Aventis` vaccine division will license Crucell`s cell line technology to make the vaccines and will in return give Crucell (NasdaqNM:CRXL - News) payments and research funding totaling $38 million.
Aventis, a Franco-German drugmaker which is one of world`s few makers of flu vaccines, would also give Netherlands-based Crucell royalties on vaccine sales in the high-single-digit to double-digit percentage range.
But Raterink added that various questions were left unanswered, such as the timeframe over which the Aventis payments would be received by Crucell.
"With a current market capitalisation of 228 or 229 million euros, Crucell`s share price jump of over 20 percent implies that future gains have already been factored in now," he added.
Aventis shares were more than two percent lower at 50.95 euros in afternoon trade.
Email this story - Set a News Alert
was sag ich schon so lange............
it`s a blockbuster............
up, up and away...........
Grüße
m e r x,
http://www.batv.com/custom/video.asp?rmbase=genemax2
Hört euch mal dies an .............
long und schrong
m e r x
Hört euch mal dies an .............
long und schrong
m e r x
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 220 | ||
| 112 | ||
| 108 | ||
| 76 | ||
| 44 | ||
| 43 | ||
| 39 | ||
| 35 | ||
| 33 | ||
| 32 |
| Wertpapier | Beiträge | |
|---|---|---|
| 31 | ||
| 26 | ||
| 26 | ||
| 24 | ||
| 24 | ||
| 22 | ||
| 22 | ||
| 20 | ||
| 19 | ||
| 18 |
